Impact of Nirsevimab on RSV and Non‐RSV Severe Respiratory Infections in Hospitalized Infants
Nirsevimab introduction was significantly associated with reduced hospitalizations and severity of RSV and other respiratory infections. Its use was associated with fewer admissions and reduced need for intensive care, especially in RSV-infected infants but also in HMPV and adenovirus-infected infants.
Authors
- Inmaculada Casas (ORCID: https://orcid.org/0000-0003-1840-1198)
- Cristina Calvo (ORCID: https://orcid.org/0000-0002-6503-3423)
- María Luz García‐García (ORCID: https://orcid.org/0000-0003-4906-4227)
- Francisco Pozo (ORCID: https://orcid.org/0000-0003-1828-733X)
- Jara Hurtado‐Gallego (ORCID: https://orcid.org/0000-0003-2509-857X)
- Patricia Alonso‐López
- Sonia Alcolea (ORCID: https://orcid.org/0000-0003-1233-1723)
- María Iglesias‐Caballero (ORCID: https://orcid.org/0000-0002-3248-4471)
- María Arroyas (ORCID: https://orcid.org/0000-0002-8717-0322)
- Rocío Sánchez‐León (ORCID: https://orcid.org/0000-0002-4835-8306)
Institutions
- Society for Endocrinology (GB)
- Instituto de Salud Carlos III (ES)
- Hospital La Paz Institute for Health Research (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Centro de Investigación Biomédica en Red (ES)
- Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (ES)
- Hospital Universitario Severo Ochoa (ES)
Publication Details
- Journal
- Influenza and Other Respiratory Viruses
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1111/irv.70105
- Citations
- 4
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- HORIZON EUROPE Framework Programme
- Instituto de Salud Carlos III
- HORIZON EUROPE Health